secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001193125-25-024814
Event type: other_material
Sentiment:  positive
Materiality: 0.78
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience reports favorable ALTO-300 Phase 2b interim analysis; final data expected mid-2026
--------------------------------------------------------------------------------

- Planned interim analysis recommended continuing study with ~200 biomarker-positive patients in final sample.
- Topline results from the Phase 2b trial of ALTO-300 are expected in mid-2026.
- Company reported preliminary 2024 year-end cash of ~$168M, expected to fund operations into 2028.
- Interim analysis included 87 biomarker-positive patients after in-depth site and patient eligibility review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000119312525024814/0001193125-25-024814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000119312525024814/d876505d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-024814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer